Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of skin toxicity dosing of IRESSA (gefitinib) as monotherapy in recurrent and/or metastatic squamous cell carcinoma of the head and neck

Trial Profile

Phase II study of skin toxicity dosing of IRESSA (gefitinib) as monotherapy in recurrent and/or metastatic squamous cell carcinoma of the head and neck

Suspended
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2006

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Dec 2006 Status change
    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top